清宣止咳颗粒联合乙酰半胱氨酸泡腾片治疗慢性阻塞性肺疾病的临床效果

摘要
图/表
参考文献(22)
相关文章 (15)

全文: PDF (406 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨清宣止咳颗粒联合乙酰半胱氨酸泡腾片对慢性阻塞性肺疾病（COPD）患者的影响。方法选择2017年1月～2018年6月中国人民解放军联勤保障部队第九〇四医院收治的COPD患者103例，按照随机数字表法将患者分为对照组（51例）和观察组（52例）。对照组患者给予乙酰半胱氨酸泡腾片治疗，观察组在对照组的基础上联合清宣止咳颗粒治疗。观察两组治疗后临床疗效，比较两组治疗前后炎性因子[白介素-6（IL-6）、白介素-8（IL-8）、肿瘤坏死因子-α（TNF-α）]、肺功能[用力肺活量（FVC）、第1秒用力呼气容积（FEV1）、最大呼气峰流速（PEF）、第1秒用力呼气容积占用力肺活量之比（FEV1/FVC）]、血气分析[氧分压（PO2）、血氧饱和度（SaO2）、二氧化碳分压（PCO2）]，记录两组患者治疗期间不良反应。结果观察组治疗后总有效率显著高于对照组（P ＜ 0.05）。两组患者治疗后IL-6、IL-8及TNF-α均低于治疗前，且观察组低于对照组（P ＜ 0.05）。两组患者治疗后FVC、FEV1、PEF、FEV1/FVC均较治疗前升高，且观察组高于对照组（P ＜ 0.05）。两组患者治疗后PO2、SaO2均较治疗前升高，且观察组高于对照组（P ＜ 0.05）；PCO2较治疗前降低，且观察组低于对照组（P ＜ 0.05）。两组不良反应发生率比较差异无统计学意义（P ＞ 0.05）。结论清宣止咳颗粒联合乙酰半胱氨酸泡腾片治疗COPD效果确切，可显著改善患者肺功能、动脉血气指标，减轻患者炎性反应，且不增加不良反应发生率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	姜鑫鑫1 钱晓凌1 张维维2 盛馨月1 吴可人2

关键词 ：清宣止咳颗粒, 乙酰半胱氨酸泡腾片, 慢性阻塞性肺疾病

Abstract：Objective To investigate the effects of Qingxuan Zhike Granules combined with Acetylcysteine Effervescent Tablets on patients with chronic obstructive pulmonary disease (COPD). Methods One hundred and three patients with COPD admitted to the 904th Hospital of PLA Joint Logistics Support Force from January 2017 to June 2018 were selected and divided into control group (51 cases) and observation group (52 cases) according to the random number table method. The control group was given Acetylcysteine Effervescent Tablets, and the observation group was treated with Qingxuan Zhike Granules on the basis of the control group. The clinical effects of the two groups after treatment were observed, the inflammatory factors [interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α)], pulmonary function [forced vital capacity (FVC), forced expiratory volume in one second (FEV1), peak expiratory flow rate (PEF), the ratio of FEV1 to FVC], blood gas analysis [oxygen partial pressure (PO2), blood oxygen saturation (SaO2), partial pressure of carbon dioxide (PCO2)] were compared between the two groups before and after treatment, and the adverse reactions of the two groups were recorded during the treatment. Results After treatment, the total effective rate of the observation group was significantly higher than that of the control group (P ＜ 0.05). After treatment, the levels of IL-6, IL-8 and TNF-α in the two groups were lower than those before treatment, which in the observation group were lower than those in the control group (P ＜ 0.05). After treatment, FVC, FEV1, PEF, the FEV1 to FVC radio in both groups were higher than those before treatment, which of the observation group were higher than those of the control group (P ＜ 0.05). After treatment, PO2 and SaO2 in both groups were higher than those before treatment, which of the observation group were higher than those of the control group (P ＜ 0.05); PCO2 was lower than before treatment, which of the observation group was lower than that of the control group (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Qingxuan Zhike Granule combined with Acetylcysteine Effervescent Tablets is effective in the treatment of COPD, which can significantly improve the pulmonary function, arterial blood gas index, alleviate inflammatory reactions, and does not increase the incidence of adverse reactions.

Key words： Qingxuan Zhike Granules Acetylcysteine Effervescent Tablets Chronic obstructive pulmonary disease

基金资助:江苏省卫生计生委医学科研课题（H201567）。

通讯作者: 钱晓凌（1966.5-），女，主任药师，主要从事药学方向的研究。

引用本文:

姜鑫鑫1 钱晓凌1 张维维2 盛馨月1 吴可人2. 清宣止咳颗粒联合乙酰半胱氨酸泡腾片治疗慢性阻塞性肺疾病的临床效果[J]. 中国医药导报, 2019, 16(9): 123-126.
JIANG Xinxin1 QIAN Xiaoling1 ZHANG Weiwei2 SHENG Xinyue1 WU Keren2. Clinical efficacy of Qingxuan Zhike Granules combined with Acetylcysteine Effervescent Tablets in treating chronic obstructive pulmonary disease. 中国医药导报, 2019, 16(9): 123-126.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2019/V16/I9/123

[1] Badnjevic A，Gurbeta L，Custovic E. An Expert Diagnostic System to Automatically Identify Asthma and Chronic Obstructive Pulmonary Disease in Clinical Settings [J]. Sci Rep，2018，8（1）：11645.
[2] 倪明德，文强，钱强，等.老年慢性阻塞性肺疾病合并肺结核感染的临床观察[J].中华医院感染学杂志，2015，35（7）：1560-1561，1581.
[3] 迟玉敏，邸庆国，李敏，等.乙酰半胱氨酸泡腾片治疗慢性阻塞性肺疾病的临床研究[J].中国临床药理学杂志，2018，34（7）：763-766.
[4] 郑媛，唐玲，李珊珊，等.清宣止咳颗粒治疗儿童急性上呼吸道感染的临床观察[J].中国医药导刊，2015，17（1）：76-77，79.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）（一）[J].中华结核和呼吸杂志，2013，36（4）：255-264.
[6] 李锐，刘新，卢来春，等.沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病急性加重期疗效和安全性的Meta分析[J].中国药房，2015，26（21）：2950-2953.
[7] 肖建，杜春玲.慢性阻塞性肺疾病病因及发病机制研究进展[J].中国老年学杂志，2014，34（11）：3191-3194.
[8] 于仁志，韩磊，姜爱英，等.布地奈德福莫特罗治疗支气管哮喘-慢性阻塞性肺疾病重叠综合征43例疗效观察[J].中国药业，2017，26（21）：61-63.
[9] Abadias Medrano MJ，Yuguero Torres O，Bardés Robles I，et al. Exacerbations of chronic obstructive pulmonary disease：An analysis of the care process in a regional hospital emergency department [J]. Medicine（Baltimore），2018，97（31）：e11601.
[10] Jensen D，Schaeffer MR，Guenette JA. Pathophysiological mechanisms of exertional breathlessness in chronic obstructive pulmonary disease and interstitial lung disease [J]. Curr Opin Support Palliat Care，2018，12（3）：237-245.
[11] 周洋，张家洪，黄河，等.乙酰半胱氨酸泡腾片对慢性阻塞性肺疾病患者炎性反应及氧化/抗氧化失衡的影响研究[J].检验医学与临床，2014，11（5）：668-669.
[12] 魏安银.N-乙酰半胱氨酸对Ⅲ期尘肺并发慢性阻塞性肺疾病的疗效[J].中华劳动卫生职业病杂志，2015，33（1）：55-56.
[13] Liu YM，Liu Y，Lu C，et al. Relative bioavailability of generic and branded acetylcysteine effervescent tablets：A single-dose，open-label，randomized-sequence，two-period crossover study in fasting healthy Chinese male volunteers [J]. Clin Ther，2010，32（12）：2097-2105.
[14] 王明航，李建生.中医药治疗慢性阻塞性肺疾病临床疗效评价研究现状[J].中医杂志，2017，58（3）：258-261.
[15] 朱正刚，陈燕，石溪溪，等.慢性阻塞性肺疾病患者中医传统健身功法呼吸功能锻炼现状[J].中国老年学杂志，2016，36（14）：3556-3558.
[16] 洪凡青.清宣止咳颗粒与盐酸氨溴索口服液联合治疗小儿急性上呼吸道感染的疗效观察[J].中国医院用药评价与分析，2016，16（5）：588-590.
[17] 王灿灿，冯月娟，郁东伟，等.乙酰半胱氨酸泡腾片治疗阻塞性睡眠呼吸暂停低通气综合征的临床研究[J].中国临床药理学杂志，2017，33（21）：2104-2106.
[18] 蔺建英，董喆.清宣止咳颗粒治疗小儿支气管肺炎疗效观察[J].光明中医，2017，32（15）：2158-2159.
[19] 王晓敏，蔡建新，徐和祥，等.小儿宣肺止咳颗粒治疗小儿急性支气管炎的理论发微[J].世界中医药，2016，11（5）：917-918.
[20] 郁宇宏.清宣止咳颗粒联合王氏保赤丸外敷治疗小儿支气管肺炎的应用探析[J].内蒙古中医药，2017，36（18）：65.[21] 吴中华，闫玲玲，杨爱东，等.鱼腥草素钠对慢性阻塞性肺疾病模型大鼠肺组织PI3K、AKT1及mTOR mRNA表达的影响[J].中国实验动物学报，2018，26（1）：8-12.
[22] 何森，陈寒，彭青和，等.从肺朝百脉论治慢性阻塞性肺疾病[J].长春中医药大学学报，2013，29（1）：90-92.